Drug reference
Laronidase is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in the treatment of non-neurological manifestations of mucopolysaccharidosis I, a lysosomal storage disorder caused by deficiency of alpha-L- iduronidase.
PDF page 1150
Non-neurological manifestations of mucopolysaccharidosis I (specialist use only) ▶BY INTRAVENOUS INFUSION ▶Adult: 100 units/kg once weekly
PDF page 1150
Infusion-related reactions can occur
PDF page 1150
→Appendix 1: laronidase
PDF page 1150
▶Common or very common Abdominal pain. alopecia. anaphylactic reaction. angioedema. chills. cough. diarrhoea. dizziness. dyspnoea. fatigue. fever. flushing. headache. hypotension. influenza like illness. joint disorders. nausea. pain. pallor. paraesthesia. peripheral coldness. respiratory disorders. restlessness. skin reactions. sweat changes. tachycardia. temperature sensation altered. vomiting ▶Frequency not known Cyanosis. hypoxia. oedema SIDE-EFFECTS, FURTHER INFORMATION Infusion-related reactions often occur, they can be managed by slowing the infusion rate or interrupting the infusion, and can be minimised by pre-treatment with an antihistamine and an antipyretic. Recurrent infusion-related reactions may require pre-treatment with a corticosteroid—consult product literature for details.
PDF page 1150
Manufacturer advises avoid unless essential—no information available.
PDF page 1150
Manufacturer advises avoid—no information available.
PDF page 1150
Monitor immunoglobulin G (IgG) antibody concentration.
PDF page 1150
For intravenous infusion (Aldurazyme ®), give intermittently in Sodium chloride 0.9%; body-weight under 20 kg, use 100 mL infusion fluid; body-weight over 20 kg use 250 mL infusion fluid; withdraw volume of infusion fluid equivalent to volume of laronidase concentrate being added; give through in-line filter (0.22 micron) initially at a rate of 2 units/kg/hour then increase gradually every 15 minutes to max. 43 units/kg/hour.
PDF page 1150
There can be variation in the licensing of different medicines containing the same drug. Solution for infusion ELECTROLYTES: May contain Sodium ▶Aldurazyme (Genzyme Therapeutics Ltd) Laronidase 100 unit per 1 ml Aldurazyme 500units/5ml solution for infusion vials | 1 vial P £444.70 2.9 Niemann-Pick type C disease ENZYME INHIBITORS › GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
PDF page 1150
100 units/kg once weekly
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1150
